Label counts behind armodafinil side effects
The label counts armodafinil side effects that led people to stop.
In placebo-controlled clinical trials, 44 of the 645 patients (7%) who received NUVIGIL discontinued due to an adverse reaction compared to 16 of the 445 (4%) of patients that received placebo.
In the trials, 44 of the 645 patients (7%) who received NUVIGIL stopped.
On placebo, 16 of the 445 patients (4%) stopped.
The label says the most frequent reason for stopping was headache (1%).
The label says serious rash has been reported with NUVIGIL (armodafinil) or modafinil.
The highlights say to stop NUVIGIL at the first sign of rash.
They add one exception: a rash that is clearly not drug-related.
Follow your doctor for any decision about this drug.
Sources
- dailymed-nuvigil retrieved 2026-11-18